60 years blank! "Hyperkalemia" ushers in the first new drug!

AstraZeneca official announcement: the new oral potassium reducing drug ribeizhuo (general name: sodium zirconate cyclosilicate powder) has been approved by the State Drug Administration of China for marketing, and is used to treat adult hyperkalemia The drug treatment of hyperkalemia has experienced a blank period of nearly 60 years As the first innovative drug on the market in China, the approval of sodium zirconate cyclosilicate powder marks a new era of hyperkalemia treatment in China In the first half of 2019, because of its unique mechanism of action and clinical efficacy, sodium zirconate cyclosilicate powder can help patients with hyperkalemia to solve the unmet treatment needs It was included in the second batch of "list of clinically urgent overseas new drugs" by the drug review center of the State Drug Administration, and was first reviewed and approved Hyperkalemia (serum potassium level > 5.0mmol/L) is one of the important complications of chronic kidney disease and heart failure The incidence rate gradually increases with the progression of disease, and the recurrence and interval gradually shorten Chronic kidney disease is the sixth leading cause of death in China: the incidence rate is as high as 10.8%, the number of patients is over 100 million, and nearly 40% of them suffer from death due to arrhythmia / cardiac arrest With the approval of sodium zirconate cyclosilicate powder, it brings hope for the huge clinical demand of Chinese hyperkalemia patients Adorable adorable